BioCentury
ARTICLE | Product Development

Early Pfizer data from DGAT2-targeting NASH program lay groundwork for monotherapy and combos

Eearly Pfizer data from DGAT2-targeting NASH program lay groundwork for monotherapy, combos

November 27, 2019 10:31 PM UTC
Updated on Dec 5, 2019 at 11:30 PM UTC

Pfizer thinks Phase I and preclinical data from its DGAT2 program suggest the target could hit NASH's three mechanistic pillars -- dysregulated metabolism, inflammation and fibrosis. The pharma is advancing a next-generation compound both alone and in combination with its ACC inhibitor.

In a Science Translational Medicine study published Wednesday, researchers from Pfizer Inc. (NYSE:PFE) showed the DGAT2 inhibitor PF-06427878 decreased hepatic steatosis and increased liver function in healthy adults and in rodent models of non-alcoholic steatohepatitis (NASH)...

BCIQ Company Profiles

Pfizer Inc.